

Human Recombinant Adenosine A2B Receptor Stable Cell Line Cat. No. M00329

Version 05282014

. 1
. 1
. 2
2
3
. 4

I. INTRODUCTION

Catalog Number: M00329

Cell Line Name: CHO-K1/ADORA2B/Gα15

Gene Synonyms: ADORA2B;

Expressed Gene: Genbank Accession Number NM_000676; no expressed tags

Host Cell: CHO-K1/Gα15

Quantity: Two vials of frozen cells (3×10⁶ per vial)

Stability: 16 passages

Application: Functional assay for ADORA2B receptor

Freeze Medium: 45% culture medium, 45% FBS, 10% DMSO

Complete Growth Medium: Ham's F12, 10% FBS

Culture Medium: Ham's F12, 10% FBS, 400 µg/ml G418, 100 µg/ml Hygromycin B

Mycoplasma Status: Negative

Storage: Liquid nitrogen immediately upon delivery

II. BACKGROUND

The adenosine receptors ADORA2B is G_s and G_q/G_{11} -coupled GPCR expressed in the large intestine, cecum, and urinary bladder. ADORA2B receptor mediates relaxation to adenosine in human small coronary arteries which is independent of NO but dependents in part on a K^+ -sensitive mechanism. Pharmacological or molecular biologic activation of ADORA2B receptor may prevent glomerular remodeling associated with glomerulosclerosis, renal disease, and abnormal growth associated with hypertension and diabetes.



III. REPRESENTATIVE DATA

Concentration-dependent stimulation of intracellular calcium mobilization by NECA in CHO-K1/ADORA2B/G α 15 and CHO-K1/G α 15 cells




Figure 1.NECA-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/ADORA2B/G α 15 and CHO-K1/G α 15 cells. The cells were loaded with Calcium-4 prior to stimulation with an ADOPA2B receptor agonist, NECA. The intracellular calcium change was measured by FlexStation. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (10-fold dilution) of NECA (Mean \pm SD, n = 2). The EC₅₀ of NECA on ADORA2B co-expressing with G α 15 in CHO-K1 cells was 14 nM. The S/B of NECA on ADORA2B co-expressing with G α 15 in CHO-K1 cells was 5.

Notes:

- 1. EC₅₀ value is calculated with four parameter logistic equation:
 - Y=Bottom + (Top-Bottom)/(1+10^((LogEC₅₀-X)*HillSlope))
 - X is the logarithm of concentration. Y is the response
 - Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.
- 2. Signal to background Ratio (S/B) = Top/Bottom

IV. THAWING AND SUBCULTURING

Thawing Protocol

- 1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
- 2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
- 3. Pellet cells by centrifugation at 200 x g force for 5 min, and remove the medium.
- 4. Resuspend the cells in complete growth medium.



- 5. Transfer the cell suspension to a 10 cm dish with 10 ml of complete growth medium.
- 6. Grow the cells in incubator with 37°C, 5 %CO₂.
- 7. In the following day, replace the cells with fresh medium contains antibiotic.

Subculturing Protocol

- 1. Remove the culture medium from cells.
- 2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution into 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).
 Note: To avoid cells clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells detach.
- 4. Add 6.0 to 8.0 ml of complete growth medium into dish and aspirate cells by gently pipetting.
- 5. Centrifuge the cells at 200 x g force for 5min, and remove the medium.
- 6. Resuspend the cells in culture medium and add the cells suspension to new culture dish.

If cells are difficult to detach, please place the dish in 37°C incubator for ~2 min.

7. Grow the cells in incubator with 37°C, 5 %CO₂.

Subcultivation Ratio: 1:3 to 1:8 weekly. Medium Renewal: Every 2 to 3 days

V. REFERENCES

- 1. Stehle JH *et al.* (1992) Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. *Mol Endocrinol.* 6(3):384-93.
- 2. Bosch MP *et al.* (2004) Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor. *J Med Chem.* 47(16):4041-53.
- 3. Kemp BK *et al.* (1999) Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors. *Br J Pharmacol.* 126(8):1796-800.
- 4. Dubey RK *et al.* (2005) Adenosine inhibits PDGF-induced growth of human glomerular mesangial cells via A(2B) receptors. *Hypertension*. 46(3):628-34. Epub 2005 Aug 15.

GenScript USA Inc.

860 Centennial Ave. Piscataway, NJ 08854 Toll-Free: 1-877-436-7274

Tel: 1-732-885-9188, Fax: 1-732-210-0262

Email: product@genscript.com
Web: http://www.genscript.com

For Research Use Only.

- 860 Centennial Ave., Piscataway, NJ 08854, USA -



Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- The products are not transferable and will be used at the site where they were purchased. Transfer to another site
 owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by
 GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products sold by GenScript are for laboratory and animal research purposes only. The products are not to be used on humans, for consumption, or for any unlawful uses.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for other purposes, contact Marketing Department, GenScript USA Inc., 120 Centennial Avenue, Piscataway, New Jersey 08840, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: marketing@genscript.com.